Производител
GlaxoSmithKline Biologicals SA
17 продукта в каталога
| Търговско име | Концентрация | Форма |
|---|---|---|
| Adjupanrix | --¹ After mixing, 1 dose (0.5 ml) contains: Split influenza virus, inactivated, containing antigen* equivalent to: A/VietNam/1194/2004 (H5N1) like strain used (NIBRG-14) 3.75 μg** * propagated in eggs ** haemagglutinin AS03 adjuvant composed of squalene (10.69 mg), DL-alfa-tocopherol (11.86 mg) and polysorbate 80 (4.86 mg) | Emulsion and suspension for emulsion for injection |
| Ambirix | --¹ 1 dose (1 ml) contains: Hepatitis A virus (inactivated)¹,² 720 ELISA Units Hepatitis B surface antigen³,⁴ 20 micrograms ¹Produced on human diploid (MRC-5) cells ²Adsorbed on aluminium hydroxide, hydrated 0.05 milligrams Al³+ ³Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology ⁴Adsorbed on aluminium phosphate 0.4 milligrams Al³+ | инжекционна суспензия |
| Boostrix | suspension for injection in pre-filled syringe | суспензия за инжектиране |
| Boostrix | — | инжекционна суспензия |
| Boostrix Polio | suspension for injection in pre-filled syringe | суспензия за инжектиране |
| Cervarix | --¹ 1 dose (0.5 ml) contains: Human Papillomavirus1 type 16 L1 protein²,³,⁴ 20 micrograms Human Papillomavirus1 type 18 L1 protein²,³,⁴ 20 micrograms 1Human Papillomavirus = HPV ²adjuvanted by AS04 containing: 3-O-desacyl-4’- monophosphoryl lipid A (MPL)³ 50 micrograms ³ adsorbed on aluminium hydroxide, hydrated (Al(OH)₃) 0.5 milligrams Al³+ in total ⁴L1 protein in the form of non-infectious virus-like particles (VLPs) produced by recombinant DNA technology using a Baculovirus expression system which uses Hi-5 Rix4446 cells derived from Trichoplusia ni. | инжекционна суспензия |
| Fluarix Tetra | suspension for injection in pre-filled syringe | суспензия за инжектиране |
| Havrix 1440 | suspension for injection (adult dose) | суспензия за инжектиране |
| Havrix 720 | suspension for injection (junior monodose) | суспензия за инжектиране |
| Infanrix hexa | --¹ After reconstitution, 1 dose (0.5 ml) contains: Diphtheria toxoid, adsorbed ≥ 30 IU Tetanus toxoid, adsorbed ≥ 40 IU Pertussis toxoid, adsorbed 25 µg Filamentous haemagglutinin, adsorbed 25 µg Pertactin, adsorbed 8 µg Recombinant hepatitis B surface antigen (S protein), adsorbed 10 µg Inactivated type 1 poliovirus 40 DU Inactivated type 2 poliovirus 8 DU Inactivated type 3 poliovirus 32 DU Conjugate of Haemophilus influenzae type b capsular polysaccharide (PRP) 10 µg and tetanus toxoid (T), adsorbed (PRP-T) approximately 25 µg | прах и суспенсия за инжекционна суспенсия |
| Infanrix-IPV+Hib | powder and suspension for suspension for injection | прах и суспенсия за инжекционна суспенсия |
| Priorix | powder and solvent for solution for injection | прах и разтворител за инжекционен разтвор |
| Priorix-Tetra | powder and solvent for solution for injection | прах и разтворител за инжекционен разтвор |
| Shingrix | --¹ After reconstitution, one dose (0.5 mL) contains: Varicella Zoster Virus¹ glycoprotein E antigen²,³ 50 micrograms ¹ Varicella Zoster Virus = VZV ² adjuvanted with AS01B containing: plant extract Quillaja saponaria Molina, fraction 21 (QS-21) 50 micrograms 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota 50 micrograms ³ glycoprotein E (gE) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology | прах и суспенсия за инжекционна суспенсия |
| Synflorix | --¹ 1 dose (0.5 ml) contains: Pneumococcal polysaccharide serotype 1* ¹ 1 microgram Pneumococcal polysaccharide serotype 4* ¹ 3 micrograms Pneumococcal polysaccharide serotype 5* ¹ 1 microgram Pneumococcal polysaccharide serotype 6B* ¹ 1 microgram Pneumococcal polysaccharide serotype 7F* ¹ 1 microgram Pneumococcal polysaccharide serotype 9V* ¹ 1 microgram Pneumococcal polysaccharide serotype 14* ¹ 1 microgram Pneumococcal polysaccharide serotype 18C* ² 3 micrograms Pneumococcal polysaccharide serotype 19F* ³ 3 micrograms Pneumococcal polysaccharide serotype 23F* ¹ 1 microgram * adsorbed on aluminium phosphate 0.5 milligram Al³+ ¹ conjugated to protein D (derived from non-typeable Haemophilus influenzae) carrier protein 9-16 micrograms ² conjugated to tetanus toxoid carrier protein 5-10 micrograms ³ conjugated to diphtheria toxoid carrier protein 3- 6 micrograms | инжекционна суспензия |
| Twinrix Adult | 1 dose (1 ml) contains: Hepatitis A virus (inactivated)¹,² 720 ELISA Units Hepatitis B surface antigen³,4 20 micrograms ¹Produced on human diploid (MRC-5) cells ²Adsorbed on aluminium hydroxide, hydrated 0.05 milligrams Al³+ ³Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology 4Adsorbed on aluminium phosphate 0.4 milligrams Al³+ | инжекционна суспензия |
| Twinrix Paediatric | --¹ 1 dose (0.5 ml): Hepatitis A virus (inactivated)¹,² 360 ELISA Units Hepatitis B surface antigen³,⁴ 10 micrograms ¹Produced on human diploid (MRC-5) cells ²Adsorbed on aluminium hydroxide, hydrated 0.025 milligrams Al³+ ³Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology ⁴Adsorbed on aluminium phosphate 0.2 milligrams Al³+ | инжекционна суспензия |